Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Launched by GALDERMA R&D · May 16, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a medication called nemolizumab (brand name: Nemluvio®) for treating moderate-to-severe atopic dermatitis, a chronic skin condition that causes red, itchy patches. The goal is to see how well this treatment works in real-life situations over a period of six months, based on assessments by doctors and feedback from patients themselves.
To be eligible for this trial, participants must be adolescents or adults aged 12 and older who are starting treatment with nemolizumab as recommended by their doctor. They need to provide consent to join the study, either themselves or through a legal representative. However, people who cannot use nemolizumab for medical reasons, have received other experimental treatments in the last three months, or have previously used nemolizumab are not eligible to participate. Those who join the trial can expect regular check-ins to assess their progress and share their experiences with the treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
- • Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
- • Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
- Exclusion Criteria:
- • Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
- • Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
- • Participants who received nemolizumab previously.
- • Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Buxtehude, , Germany
Castle Rock, Colorado, United States
Fairfield, Connecticut, United States
Cutler Bay, Florida, United States
Brighton, Massachusetts, United States
Lee's Summit, Missouri, United States
East Syracuse, New York, United States
Dallas, Texas, United States
Berlin, , Germany
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Corona, California, United States
Fountain Valley, California, United States
Fremont, California, United States
Irvine, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
San Francisco, California, United States
Santa Monica, California, United States
Thousand Oaks, California, United States
Coral Gables, Florida, United States
Jupiter, Florida, United States
Miami, Florida, United States
Miami, Florida, United States
Miami, Florida, United States
North Miami Beach, Florida, United States
Saint Petersburg, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
West Lafayette, Indiana, United States
Columbia, Maryland, United States
Glenn Dale, Maryland, United States
Rockville, Maryland, United States
Milford, Massachusetts, United States
Auburn Hills, Michigan, United States
Caledonia, Michigan, United States
Grandville, Michigan, United States
Troy, Michigan, United States
Saint Louis, Missouri, United States
Las Vegas, Nevada, United States
Portsmouth, New Hampshire, United States
Auburn, New York, United States
Mount Kisco, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Dayton, Ohio, United States
Gresham, Oregon, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Bluffton, South Carolina, United States
Cedar Park, Texas, United States
Edinburg, Texas, United States
Grapevine, Texas, United States
Houston, Texas, United States
Sugar Land, Texas, United States
Waco, Texas, United States
Bountiful, Utah, United States
Vienna, Virginia, United States
Karlsruhe, , Germany
Langenau, , Germany
Augsburg, Bayern, Germany
Erlangen, Bayern, Germany
Regensburg, Bayern, Germany
Remscheid, Nordrhein Westfalen, Germany
Ahaus, , Germany
Augsburg, , Germany
Berlin, , Germany
Berlin, , Germany
Bernau Bei Berlin, , Germany
Bielefeld, , Germany
Gladbeck, , Germany
Großenhain, , Germany
Haslach Im Kinzigtal, , Germany
Hersbruck, , Germany
Koblenz, , Germany
Lübeck, , Germany
Mainz, , Germany
Oberursel, , Germany
Oranienburg, , Germany
Pforzheim, , Germany
Quedlinburg, , Germany
London, Hampshire, United Kingdom
Southampton, Hampshire, United Kingdom
Watford, Hertfordshire, United Kingdom
King's Lynn, Norfolk, United Kingdom
Harrogate, North Yorkshire, United Kingdom
Sheffield, South Yorkshire, United Kingdom
London, Surrey, United Kingdom
Birmingham, West Midlands, United Kingdom
Leeds, West Yorkshire, United Kingdom
York, Yorkshire, United Kingdom
Bridgend, , United Kingdom
Epsom, , United Kingdom
Harrow, , United Kingdom
Kingston Upon Thames, , United Kingdom
Liverpool, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Redhill, , United Kingdom
Sandbach, , United Kingdom
Swansea, , United Kingdom
Wirral, , United Kingdom
Wolverhampton, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported